| Print
Editas Medicine (EDIT)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Address
11 Hurley Street
Cambridge
MA
USA
02141
Telephone
+1 617 4019083
Forecast key dates
| Name | Key Date |
|---|---|
| Editas Medicine Inc Fourth Quarter Earnings Results for 2025 | 2026-03-05T00:00:00 |
| Editas Medicine Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-05T00:00:00 |
| Editas Medicine Inc Annual Report for 2025 | 2026-03-05T00:00:00 |
| Editas Medicine Inc Third Quarter Earnings Results for 2025 | 2025-11-04T00:00:00 |
| Editas Medicine Inc Second Quarter Earnings Conference Call for 2025 | 2025-08-07T08:00:00 |
| Editas Medicine Inc Second Quarter Earnings Results for 2025 | 2025-08-07T00:00:00 |
| Editas Medicine Inc Annual General Meeting for 2025 | 2025-05-30T08:30:00 |
| Editas Medicine Inc First Quarter Earnings Conference Call for 2025 | 2025-05-08T08:00:00 |
| Editas Medicine Inc First Quarter Earnings Results for 2025 | 2025-05-08T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.